Genomic aberrations and survival in chronic lymphocytic leukemia - PubMed (original) (raw)
. 2000 Dec 28;343(26):1910-6.
doi: 10.1056/NEJM200012283432602.
Affiliations
- PMID: 11136261
- DOI: 10.1056/NEJM200012283432602
Free article
Genomic aberrations and survival in chronic lymphocytic leukemia
H Döhner et al. N Engl J Med. 2000.
Free article
Abstract
Background: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications.
Methods: Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22-23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings.
Results: Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (7 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information.
Conclusions: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies.
Comment in
- Chromosomal abnormalities in chronic lymphocytic leukemia.
Garcia-Manero G. Garcia-Manero G. N Engl J Med. 2001 Apr 19;344(16):1254. doi: 10.1056/NEJM200104193441615. N Engl J Med. 2001. PMID: 11314693 No abstract available.
Similar articles
- Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia.
Durak B, Akay OM, Aslan V, Ozdemir M, Sahin F, Artan S, Gülbas Z. Durak B, et al. Cancer Genet Cytogenet. 2009 Jan 15;188(2):65-9. doi: 10.1016/j.cancergencyto.2008.08.019. Cancer Genet Cytogenet. 2009. PMID: 19100507 - Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A. Quijano S, et al. Cytometry B Clin Cytom. 2008 May;74(3):139-49. doi: 10.1002/cyto.b.20390. Cytometry B Clin Cytom. 2008. PMID: 18061951 - Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Cavazzini F, Milani R, Minotto C, Tieghi A, Della Porta M, Agostini P, Tammiso E, Negrini M, Castoldi G. Cuneo A, et al. Haematologica. 2002 Jan;87(1):44-51. Haematologica. 2002. PMID: 11801464 - Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Stilgenbauer S, et al. Leukemia. 2002 Jun;16(6):993-1007. doi: 10.1038/sj.leu.2402537. Leukemia. 2002. PMID: 12040431 Review.
Cited by
- From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.
Ahmadi SE, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M, Safdari SM, Shabannezhad A, Jaafari N, Safa M. Ahmadi SE, et al. Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9. Biomark Res. 2024. PMID: 39538363 Free PMC article. Review. - Association of Genetic Variants at the CDKN1B and CCND2 Loci Encoding p27_Kip1_ and Cyclin D2 Cell Cycle Regulators with Susceptibility and Clinical Course of Chronic Lymphocytic Leukemia.
Ciszak L, Kosmaczewska A, Pawlak E, Frydecka I, Szteblich A, Wołowiec D. Ciszak L, et al. Int J Mol Sci. 2024 Oct 31;25(21):11705. doi: 10.3390/ijms252111705. Int J Mol Sci. 2024. PMID: 39519258 Free PMC article. - Complex karyotypes in hematologic disorders: a 12-year single-center study from Lebanon.
Rammal S, Abou Abdallah F, Attieh C, El Mounajjed Z, Semaan W, Chebly A. Rammal S, et al. Front Oncol. 2024 Oct 24;14:1480793. doi: 10.3389/fonc.2024.1480793. eCollection 2024. Front Oncol. 2024. PMID: 39512772 Free PMC article. - Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL).
Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Sekar A, et al. Blood Cancer J. 2024 Nov 6;14(1):193. doi: 10.1038/s41408-024-01175-8. Blood Cancer J. 2024. PMID: 39505849 Free PMC article. - First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis.
Miyamoto K, Ohmoto A, Yoneoka D, Rahman MO, Ota E. Miyamoto K, et al. Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD015169. doi: 10.1002/14651858.CD015169. Cochrane Database Syst Rev. 2024. PMID: 39474946 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources